Barclays Reiterates an 'Overweight' on Halozyme Therapeutics (HALO); Focusing on Late Stage Opportunities
Tweet Send to a Friend
Barclays reiterates an Overweight rating on Halozyme Therapeutics (Nasdaq: HALO), price target $12.
Barclays analyst says, "We are reiterating our rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "We are reiterating our rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
